Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ocumension Acquires China Rights to Ocular Inflammation Product in $12 Million Deal

publication date: Jan 30, 2020

Ocumension, a China ophthalmology company, announced a $12 million agreement for Greater China rights to Dexycu® 9%, a treatment for inflammation following ocular surgery, from EyePoint Pharma (NSDQ: EYPT) of Massachusetts. Dexycu® 9%, a sustained release product, can provide a benefit for up to 22 days following cataract surgery. Ocumension will pay $2 million upfront and also make up to $10 million in milestone payments, plus royalties. Ocumension was established by 6 Dimensions Capital in 2018 to in-license ophthalmology products for China use. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital